|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: A review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
3
|
LaGory EL, Wu C, Taniguchi CM, Ding CC,
Chi JT, von Eyben R, Scott DA, Richardson AD and Giaccia AJ:
Suppression of PGC-1α is critical for reprogramming oxidative
metabolism in renal cell carcinoma. Cell Rep. 12:116–127. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frank I, Blute ML, Cheville JC, Lohse CM,
Weaver AL and Zincke H: An outcome prediction model for patients
with clear cell renal cell carcinoma treated with radical
nephrectomy based on tumor stage, size, grade and necrosis: The
SSIGN score. J Urol. 168:2395–2400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seliger B, Dressler SP, Lichtenfels R and
Kellner R: Candidate biomarkers in renal cell carcinoma.
Proteomics. 7:4601–4612. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Z, Yang F, Wei D, Liu B, Chen C, Bao Y,
Wu Z, Wu D, Tan H, Li J, et al: Long noncoding RNA-SRLR elicits
intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal
cell carcinoma. Oncogene. 36:1965–1977. 2017. View Article : Google Scholar
|
|
9
|
Orkin SH and Zon LI: Hematopoiesis: An
evolving paradigm for stem cell biology. Cell. 132:631–644. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu T, Trojanowska M and Watson DK: Ets
proteins in biological control and cancer. J Cell Biochem.
91:896–903. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosmarin AG, Resendes KK, Yang Z, McMillan
JN and Fleming SL: GA-binding protein transcription factor: A
review of GABP as an integrator of intracellular signaling and
protein-protein interactions. Blood Cells Mol Dis. 32:143–154.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
LaMarco K, Thompson CC, Byers BP, Walton
EM and McKnight SL: Identification of Ets- and notch-related
subunits in GA binding protein. Science. 253:789–792. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Polansky H and Javaherian A: Commentary:
The unliganded glucocorticoid receptor positively regulates the
tumor suppressor gene BRCA1 through GABP beta. Front Cell Infect
Microbiol. 5:662015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El-Aarag SA, Mahmoud A, Hashem MH, Abd
Elkader H, Hemeida AE and ElHefnawi M: In silico identification of
potential key regulatory factors in smoking-induced lung cancer.
BMC Med Genomics. 10:402017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang T, Xu M, Makowski MM, Lee C, Kovacs
M, Fang J, Willems E, Trent JM, Hayward NK, Vermeulen M, et al:
SDHD promoter mutations ablate GABP transcription factor binding in
melanoma. Cancer Res. 77:1649–1661. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Simmonds P, Loomis E and Curry E: DNA
methylation-based chromatin compartments and ChIP-seq profiles
reveal transcriptional drivers of prostate carcinogenesis. Genome
Med. 9:542017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Clough E and Barrett T: The Gene
Expression Omnibus Database. Methods Mol Biol. 1418:93–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wotschofsky Z, Gummlich L, Liep J, Stephan
C, Kilic E, Jung K, Billaud JN and Meyer HA: Integrated microRNA
and mRNA signature associated with the transition from the locally
confined to the metastasized clear cell renal cell carcinoma
exemplified by miR-146-5p. PLoS One. 11:e01487462016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz
KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et
al: Patterns of gene expression and copy-number alterations in
von-hippel lindau disease-associated and sporadic clear cell
carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jones J, Otu H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:e742502013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Collett D: Modelling survival data in
medical research. 3rd edition. CRC Press; Bristol: pp. 5482015
|
|
26
|
Duan Q, Flynn C, Niepel M, Hafner M,
Muhlich JL, Fernandez NF, Rouillard AD, Tan CM, Chen EY, Golub TR,
et al: LINCS Canvas Browser: Interactive web app to query, browse
and inter-rogate LINCS L1000 gene expression signatures. Nucleic
Acids Res. 42:W449–W460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue HH, Bollenbacher J, Rovella V,
Tripuraneni R, Du YB, Liu CY, Williams A, McCoy JP and Leonard WJ:
GA binding protein regulates interleukin 7 receptor alpha-chain
gene expression in T cells. Nat Immunol. 5:1036–1044. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xue HH, Bollenbacher-Reilley J, Wu Z,
Spolski R, Jing X, Zhang YC, McCoy JP and Leonard WJ: The
transcription factor GABP is a critical regulator of B lymphocyte
development. Immunity. 26:421–431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang ZF, Drumea K, Cormier J, Wang J, Zhu
X and Rosmarin AG: GABP transcription factor is required for
myeloid differentiation, in part, through its control of Gfi-1
expression. Blood. 118:2243–2253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Manukjan G, Ripperger T, Santer L, von
Neuhoff N, Ganser A, Schambach A, Schlegelberger B and Steinemann
D: Expression of the ETS transcription factor GABPα is positively
correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects
imatinib sensitivity in vitro. Exp Hematol. 43:880–890. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang ZF, Mott S and Rosmarin AG: The Ets
transcription factor GABP is required for cell-cycle progression.
Nat Cell Biol. 9:339–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F,
Geng J, Tian J, Sun X, Qin F, et al: The Ets transcription factor
GABP is a component of the hippo pathway essential for growth and
antioxidant defense. Cell Rep. 3:1663–1677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Castelo-Branco P, Choufani S, Mack S,
Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D,
Merino D, et al: Methylation of the TERT promoter and risk
stratification of childhood brain tumours: An integrative genomic
and molecular study. Lancet Oncol. 14:534–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shay JW and Bacchetti S: A survey of
telomerase activity in human cancer. Eur J Cancer. 33:787–791.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bell RJ, Rube HT, Kreig A, Mancini A,
Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, et al:
Cancer. The transcription factor GABP selectively binds and
activates the mutant TERT promoter in cancer. Science.
348:1036–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shapiro GI: Cyclin-dependent kinase
pathways as targets for cancer treatment. J Clin Oncol.
24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cazzalini O, Scovassi AI, Savio M, Stivala
LA and Prosperi E: Multiple roles of the cell cycle inhibitor
p21(CDKN1A) in the DNA damage response. Mutat Res. 704:12–20. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ritter HD, Antonova L and Mueller CR: The
unliganded glucocorticoid receptor positively regulates the tumor
suppressor gene BRCA1 through GABP beta. Mol Cancer Res.
10:558–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Somasundaram K, Zhang H, Zeng YX, Houvras
Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL and El-Deiry WS:
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires
the CDK-inhibitor p21WAF1/CiP1. Nature. 389:187–190.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Murai M and Oya M: Renal cell carcinoma:
Etiology, incidence and epidemiology. Curr Opin Urol. 14:229–233.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rini BI, Rathmell WK and Godley P: Renal
cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rini BI: Stabilization of disease in
patients with metastatic renal cell carcinoma using sorafenib. Nat
Clin Pract Oncol. 3:602–603. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Motzer RJ, Bacik J, Schwartz LH, Reuter V,
Russo P, Marion S and Mazumdar M: Prognostic factors for survival
in previously treated patients with metastatic renal cell
carcinoma. J Clin Oncol. 22:454–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Eccles SA: Heparanase: Breaking down
barriers in tumors. Nat Med. 5:735–736. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Engbring JA and Kleinman HK: The basement
membrane matrix in malignancy. J Pathol. 200:465–470. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vlodavsky I, Beckhove P, Lerner I, Pisano
C, Meirovitz A, Ilan N and Elkin M: Significance of heparanase in
cancer and inflammation. Cancer Microenviron. 5:115–132. 2012.
View Article : Google Scholar :
|
|
49
|
Jiang P, Kumar A, Parrillo JE, Dempsey LA,
Platt JL, Prinz RA and Xu X: Cloning and characterization of the
human heparanase-1 (HPR1) gene promoter: Role of GA-binding protein
and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem.
277:8989–8998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rao G, Liu D, Xing M, Tauler J, Prinz RA
and Xu X: Induction of heparanase-1 expression by mutant B-Raf
kinase: Role of GA binding protein in heparanase-1 promoter
activation. Neoplasia. 12:946–956. 2010. View Article : Google Scholar : PubMed/NCBI
|
